The platelet Fc receptor, FcγRIIa

Immunological Reviews

Volumn 268, Issue 1, 2015, Pages 241-252

  Qiao, Jianlin ^a   Al Tamimi, Mohammad ^b   Baker, Ross I ^c   Andrews, Robert K ^a   Gardiner, Elizabeth E ^a  

^a MONASH UNIVERSITY   (Australia)

^b HASHEMITE UNIVERSITY   (Jordan)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

Glycoprotein; Metalloproteinase; Platelet; Thrombocytopenia

Indexed keywords

ADAM10 ENDOPEPTIDASE; AUTOANTIBODY; AUTOANTIGEN; C REACTIVE PROTEIN; CD31 ANTIGEN; CORTICOSTEROID; ELTROMBOPAG; FC RECEPTOR IIA; FIBRINOGEN; FIBRINOGEN RECEPTOR; FOSTAMATINIB; GLYCOPROTEIN VI; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTEGRIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEINASE ACTIVATED RECEPTOR; RITUXIMAB; ROMIPLOSTIM; SIALIDASE INHIBITOR; THROMBOXANE RECEPTOR; BIOLOGICAL MARKER; FC RECEPTOR; HEPARIN; IMMUNOGLOBULIN G; PLATELET MEMBRANE GLYCOPROTEIN VI; PROTEIN BINDING;

ALLOTYPE; AMINO ACID SUBSTITUTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; GENOTYPE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOLOGY; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; INTRACELLULAR SIGNALING; MACROPHAGE; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPLENECTOMY; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE MEMBRANE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; ANIMAL; CHEMISTRY; DISEASE MANAGEMENT; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; METABOLISM; PROTEIN DEGRADATION; PROTEIN DOMAIN; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION;

ANIMALS; BIOMARKERS; BLOOD PLATELETS; DISEASE MANAGEMENT; GENOTYPE; HEPARIN; HUMANS; IMMUNOGLOBULIN G; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; POLYMORPHISM, GENETIC; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEOLYSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

EID: 84945292897     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12370     Document Type: Review

References (141)

1. Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res 2013;112:1506-1519.
2. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13:34-45.
3. Jackson SP. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med 2011;17:1423-1436.
4. Engelmann B, Spannagl M. Activators, therapeutics and immunity-related aspects of thrombosis. Thromb Haemostas 2014;111:568-569.
5. Jenne CN, Kubes P. Platelets in inflammation and infection. Platelets 2015;26:286-292.
6. Rosendaal FR, Raskob GE. On world thrombosis day. Lancet 2014;384:1653-1654.
7. Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011;11:264-274.
8. Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. J Thromb Haemost 2011;9:1097-1107.
9. Arman M, et al. Amplification of bacteria-induced platelet activation is triggered by FcγRIIA, integrin αIIbβ3 and platelet factor 4. Blood 2014;123:3166-3174.
10. Svensson L, Baumgarten M, Morgelin M, Shannon O. Platelet activation by Streptococcus pyogenes leads to entrapment in platelet aggregates, from which bacteria subsequently escape. Infect Immun 2014;82:4307-4314.
11. Kahn RA, Flinton LJ. The relationship between platelets and bacteria. Blood 1974;44:715-721.
12. Kerrigan SW, Cox D. Platelet-bacterial interactions. Cell Mol Life Sci 2010;67:513-523.
13. Arman M, Krauel K. Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis. J Thromb Haemost 2015;13:893-908.
14. McNicol A. Bacteria-induced intracellular signalling in platelets. Platelets 2015;26:309-316.
15. Rosenfeld SI, Looney RJ, Leddy JP, Phipps DC, Abraham GN, Anderson CL. Human platelet Fc receptor for immunoglobulin G. Identification as a 40, 000-molecular-weight membrane protein shared by monocytes. J Clin Invest 1985;76:2317-2322.
16. Hibbs ML, Bonadonna L, Scott BM, McKenzie IFC, Hogarth PM. Molecular cloning of a human Immunoglobulin G Fc receptor. Proc Natl Acad Sci USA 1988;85:2240-2244.
17. Powell MS, Hogarth PM. Fc receptors. Adv Exp Med Biol 2008;640:22-34.
18. Karas S, Rosse W, Kurlander R. Characterization of the IgG-Fc receptor on human platelets. Blood 1982;60:1277-1282.
19. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of FcγR by innate pentraxins. Nature 2008;456:989-992.
20. Maxwell KF, et al. Crystal structure of the human leukocyte Fc receptor, FcγRIIa. Nat Struct Biol 1999;6:437-442.
21. Ierino FL, Hulett MD, McKenzie IF, Hogarth PM. Mapping epitopes of human Fc gamma RII (CDw32) with monoclonal antibodies and recombinant receptors. J Immunol 1993;150:1794-1803.
22. Bergmeier W, Stefanini L. Platelet ITAM signaling. Curr Opin Hematol 2013;20:445-450.
23. Boulaftali Y, Hess PR, Kahn ML, Bergmeier W. Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity. Circ Res 2014;114:1174-1184.
24. Moroi AJ, Watson SP. Impact of the PI3-kinase/Akt pathway on ITAM and hemITAM receptors: haemostasis, platelet activation and antithrombotic therapy. Biochem Pharmacol 2015;94:186-194.
25. Borroto A, Abia D, Alarcón B. Crammed signaling motifs in the T-cell receptor. Immunol Lett 2014;161:113-117.
26. Horii K, Kahn ML, Herr AB. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood 2006;108:936-942.
27. Ramsland PA, et al. Structural basis for FcγRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol 2011;187:3208-3217.
28. Arthur JF, Shen Y, Kahn ML, Berndt MC, Andrews RK, Gardiner EE. Ligand binding rapidly induces disulfide-dependent dimerization of glycoprotein VI on the platelet plasma membrane. J Biol Chem 2007;282:30434-30441.
29. Jung SM, et al. Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood. J Biol Chem 2012;287:30000-30013.
30. Loyau S, et al. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. Arterioscler Thromb Vasc Biol 2012;32:778-785.
31. Bender M, et al. Combined in vivo depletion of glycoprotein VI and C-Type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice. Arterioscler Thromb Vasc Biol 2013;33:926-934.
32. Sullam PM, Hyun WC, Szollosi J, Dong J, Foss WM, Lopez JA. Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor FcγRIIa on the platelet plasma membrane. J Biol Chem 1998;273:5331-5336.
33. Zhi H, et al. Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo. Blood 2013;121:1858-1867.
34. Boylan B, Gao C, Rathore V, Gill JC, Newman DK, Newman PJ. Identification of FcγRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets. Blood 2008;112:2780-2786.
35. Canobbio I, et al. Platelet activation by von Willebrand factor requires coordinated signaling through thromboxane A2 and Fc gamma IIA receptor. J Biol Chem 2001;276:26022-26029.
36. Canobbio I, Stefanini L, Guidetti GF, Balduini C, Torti M. A new role for FcγRIIA in the potentiation of human platelet activation induced by weak stimulation. Cell Signal 2006;18:861-870.
37. Canobbio I, Balduini C, Torti M. Signalling through the platelet glycoprotein Ib-V-IX complex. Cell Signal 2004;16:1329-1344.
38. Shrimpton CN, Borthakur G, Larrucea S, Cruz MA, Dong JF, Lopez JA. Localization of the adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is required for platelet adhesion and activation. J Exp Med 2002;196:1057-1066.
39. Arthur JF, et al. ITAM receptor-mediated generation of reactive oxygen species in human platelets occurs via Syk-dependent and -independent pathways. J Thromb Haemost 2012;10:1133-1141.
40. Moseley GW. Tetraspanin-Fc receptor interactions. Platelets 2005;16:3-12.
41. Roberts JJ, Rodgers SE, Drury J, Ashman LK, Lloyd JV. Platelet activation induced by a murine monoclonal antibody directed against a novel tetra-span antigen. Br J Haematol 1995;89:853-860.
42. Gardiner EE, et al. Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcγRIIa. Blood 2008;111:165-174.
43. Vinogradov DV, et al. Inhibition of Fc-receptor dependent platelet aggregation by monoclonal antibodies against the glycoprotein IIb-IIIa complex. Biokhimiia 1991;56:787-797.
44. Horsewood P, Hayward C, Warkentin T, Kelton J. Investigation of the mechanisms of monoclonal antibody-induced platelet activation. Blood 1991;78:1019-1026.
45. Nazi I, et al. FcγRIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia. J Thromb Haemost 2013;11:1146-1153.
46. Mitrugno A, Williams D, Kerrigan SW, Moran N. A novel and essential role for FcγRIIa in cancer cell-induced platelet activation. Blood 2014;123:249-260.
47. Stein MP, et al. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest 2000;105:369-376.
48. Kapur R, et al. C-reactive protein enhances IgG-mediated phagocyte responses and thrombocytopenia. Blood 2015;125:1793-1802.
49. Hargreaves CE, et al. Fcγ receptors: genetic variation, function and disease. Immunol Rev 2015;268:6-24.
50. Tomiyama Y, Kunicki TJ, Zipf TF, Ford SB, Aster RH. Response of human platelets to activating monoclonal antibodies: importance of Fc gamma RII (CD32) phenotype and level of expression. Blood 1992;80:2261-2268.
51. Rosenfeld SI, Ryan DH, Looney RJ, Anderson CL, Abraham GN, Leddy JP. Human Fc gamma receptors: stable inter-donor variation in quantitative expression on platelets correlates with functional responses. J Immunol 1987;138:2869-2873.
52. Calverley DC, et al. Potential role of platelet FcγRIIA in collagen-mediated platelet activation associated with atherothrombosis. Atherosclerosis 2002;164:261.
53. Anderson CL, Ryan DH, Looney RJ, Leary PC. Structural polymorphism of the human monocyte 40 kilodalton Fc receptor for IgG. J Immunol 1987;138:2254-2256.
54. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding. J Immunol 1991;147:1338-1343.
55. Parren PW, et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 1992;90:1537-1546.
56. Rollin J, et al. Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. Blood 2015;125:2397-2404.
57. Norris CF, et al. A naturally occurring mutation in FcγRIIA: A Q to K127 change confers unique IgG binding properties to the R131 allelic form of the receptor. Blood 1998;91:656-662.
58. Carlsson LE, et al. Heparin-induced thrombocytopenia: new insights into the impact of the FcγRIIa-R-H131 polymorphism. Blood 1998;92:1526-1531.
59. Schallmoser K, et al. The FcγRIIa polymorphism R/H131, autoantibodies against the platelet receptors GPIbα and FcγRIIa and a risk for thromboembolism in lupus anticoagulant patients. Thromb Haemost 2005;93:544-548.
60. Kroupis C, et al. The association between a common FCGR2A polymorphism and C-reactive protein and coronary artery disease revisited. Genet Test Mol Biomarkers 2010;14:839-846.
61. Trikalinos TA, Karassa FB, Ioannidis JPA. Meta-analysis of the association between low-affinityFcγ receptor gene polymorphisms and hematologic and autoimmune diseases. Blood 2001;98:1634-1636.
62. Warmerdam PAM, Van de Winkel JG, Gosselin EJ, Capel PJA. Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J Exp Med 1990;172:19-25.
63. Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. N Engl J Med 1972;287:999-1005.
64. Grozovsky R, Hoffmeister KM, Falet H. Novel clearance mechanisms of platelets. Curr Opin Hematol 2010;17:585-589.
65. Grozovsky R, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nature Med 2015;21:47-54.
66. Mason KD, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007;128:1173-1186.
67. Cines DB, Bussel JB, Liebman HA. Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009;113:6511-6521.
68. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfusion Med Rev 2004;18:153-167.
69. Rodeghiero F, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-2393.
70. Cuker A, Cines DB. Immune thrombocytopenia. Hematology (Am Soc Hematol Educ Program) 2010;2010:377-384.
71. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 2013;98:10-23.
72. Thiagarajan P, Afshar-Kharghan V. Platelet transfusion therapy. Hem/Onc Clin N Am 2013;27:629-643.
73. Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy? Sem Thromb Hemostas 2015;41:395-404.
74. Seok J, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci 2013;110:3507-3512.
75. Davis MM. A prescription for human immunology. Immunity 2008;29:835-838.
76. Deng R, Balthasar JP. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood 2007;109:2470-2476.
77. McKenzie SE, et al. The role of the human Fc receptor FcγRIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol 1999;162:4311-4318.
78. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Nat Acad Sci 2012;109:6181-6186.
79. Petersen BH, Heim MC, White JF. Experimental drug-induced immune thrombocytopenia in monkeys. Diagn Clin Immunol 1988;5:349-354.
80. Untch B, et al. Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies. Thromb Res 2002;106:149-156.
81. Cocklin SL, Schmitz JE. The role of Fc receptors in HIV infection and vaccine efficacy. Curr Opin HIV AIDS 2014;9:257-262.
82. Trist HM, et al. Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses. J Immunol 2014;192:792-803.
83. Gardiner EE, Andrews RK. Platelets: envoys at the infection frontline. J Infect Dis 2013;208:871-873.
84. Parrula CM, Mysore J, Burr H, Freebern W, Neef N. Severe acquired idiopathic thrombocytopenia in a female cynomolgus macaque (Macaca fascicularis). Comp Med 2015;65:271-276.
85. Neunert CE. Current management of immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2013;2013:276-282.
86. Kiefel V, Freitag E, Kroll H, Santoso S, Mueller-Eckhardt C. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Ann Hematol 1996;72:280-285.
87. Nishioka T, Yamane T, Takubo T, Ohta K, Park K, Hino M. Detection of various platelet-associated immunoglobulins by flow cytometry in idiopathic thrombocytopenic purpura. Cytometry 2005;68B:37-42.
88. Huh HJ, Park CJ, Kim SW, Han SH, Jang S, Chi HS. Flow cytometric detection of platelet-associated immunoglobulin in patients with immune thrombocytopenic purpura and nonimmune thrombocytopenia. Ann Clin Lab Sci 2009;39:283-288.
89. Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen- specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996;88:194-201.
90. Hagenstrom H, Schlenke P, Hennig H, Kirchner H, Kluter H. Quantification of platelet-associated IgG for differential diagnosis of patients with thrombocytopenia. Thromb Haemost 2000;84:779-783.
91. Gardiner EE, et al. Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. J Thromb Haemost 2008;6:1175-1182.
92. Boylan B, et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRγ-chain complex from the human platelet surface. Blood 2004;104:1350-1355.
93. Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost 2009;7:322-329.
94. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010;85:174-180.
95. Neunert C, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 2015;13:457-464.
96. Panzer S, Rieger M, Vormittag R, Eichelberger B, Dunkler D, Pabinger I. Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Invest 2007;37:814-819.
97. Psaila B, et al. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost 2011;9:2302-2310.
98. Chalmers S, Tarantino MD. Romiplostim as a treatment for immune thrombocytopenia: a review. J Blood Med 2015;6:37-44.
99. Gardiner EE, et al. Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura. Brit J Haematol 2010;149:625-628.
100. Rodeghiero F, Ruggeri M. ITP and international guidelines: what do we know, what do we need? La Presse Médicale 2014;43:e61-e67.
101. Gudbrandsdottir S, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013;121:1976-1981.
102. Choi PYI, Roncolato F, Badoux X, Ramanathan S, Ho SJ, Chong BH. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood 2015;126:500-503.
103. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009;113:3154-3160.
104. Frelinger AL, et al. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood 2015;126:873-879.
105. Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transf 2011;9:262-273.
106. Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol 2014;5:674.
107. Wang D, Hu S-L, Cheng X-L, Yang J-Y. FCGR2A rs1801274 polymorphism is associated with risk of childhood-onset idiopathic (immune) thrombocytopenic purpura: evidence from a meta-analysis. Thromb Res 2014;134:1323-1327.
108. Carcao MD, et al. Fcγ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Brit J Haematol 2003;120:135-141.
109. Bruin M, et al. Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study. Brit J Haematol 2004;127:561-567.
110. Foster CB, et al. Polymorphisms in inflammatory cytokines and Fcγ receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. Brit J Haematol 2001;113:596-599.
111. Li J, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 2015;6:e7737.
112. Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost 2014;40:106-114.
113. Cuker A, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010;8:2642-2650.
114. Greinacher A. Heparin-induced thrombocytopenia. N Eng J Med 2015;373:252-261.
115. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006;355:809-817.
116. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008;112:2607-2616.
117. Prandoni P, Siragusa S, Girolami B, Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005;106:3049-3054.
118. Nguyen T-H, Greinacher A, Delcea M. Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds. Nanoscale 2015;7:10130-10139.
119. Krauel K, et al. Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011;117:1370-1378.
120. Krauel K, et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood 2012;120:3345-3352.
121. Brandt S, et al. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. Thromb Haemost 2014;112:53-64.
122. Kasthuri RS, et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood 2012;119:5285-5293.
123. Rauova L, et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood 2010;116:5021-5031.
124. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemostas 2003;1:1471-1478.
125. Kelton JG, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988;72:925-930.
126. Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood 2012;119:2209-2218.
127. Pouplard C, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99:2530-2536.
128. Scarparo P, et al. Heparin-induced thrombocytopenia: the role of platelets genetic polymorphisms. Platelets 2013;24:362-368.
129. Arepally G, McKenzie SE, Jiang XM, Poncz M, Cines DB. Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 1997;89:370-375.
130. Karnes JH, et al. A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record. Thromb Haemost 2015;113:772-781.
131. Lubenow N, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010;115:1797-1803.
132. Warkentin TE, et al. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011;9:2498-2500.
133. Greinacher A, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemostas 2007;5:1666-1673.
134. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. Annu Rev Med 2010;61:77-90.
135. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005;127:35S-45S.
136. Reilly MP, et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood 2011;117:2241-2246.
137. Poole AW. Platelet Syk is a HIT target. Blood 2011;117:2083-2084.
138. Bajpai M, Chopra P, Dastidar SG, Ray A. Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opin Investig Drugs 2008;17:641-659.
139. Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 2009;20:143-149.
140. Al-Tamimi M, et al. Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke 2011;42:498-500.
141. Gardiner EE, Andrews RK, Cuker A. Diagnostic assays for heparin-induced thrombocytopenia. Brit J Haematol 2014;166:631-633.